Afrinext Overseas Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Afrinext Overseas Private Limited Pharmaceutical Export Portfolio Dataset — 3 Products, $4.0M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Afrinext Overseas Private Limited — Pharmaceutical Exporter Profile (2026) | 3 Products, $4.0M Trade | TransData Nexus

Afrinext Overseas Private Limited

Indian Pharmaceutical Exporter · Antimalarial & Antiparasitic Specialist · $4.0M Total Trade · DGFT Verified

Afrinext Overseas Private Limited is an Indian pharmaceutical exporter with a total trade value of $4.0M across 3 products in 2 therapeutic categories. Based on 129 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Artesunate ($3.9M), Ibuprofen Paracetamol ($178.3K), Paracetamol Caffeine ($17.3K).

Afrinext Overseas Private Limited — Export Portfolio & Destination Treemap

Afrinext Overseas Private Limited pharmaceutical export portfolio — 3 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Afrinext Overseas Private Limited? — Company Overview & Market Position

Afrinext Overseas Private Limited, established on April 13, 2017, is a private limited company headquartered in Vadodara, Gujarat, India. The company is registered under the Corporate Identification Number (CIN) U74999GJ2017PTC096837 and is classified as a non-government entity. With an authorized and paid-up capital of ₹1.00 million, Afrinext has demonstrated consistent growth in the pharmaceutical export sector. As of the financial year ending March 31, 2024, the company reported a 27.98% increase in total revenue and a 41.41% rise in profit, reflecting its expanding market presence.

The company's product portfolio includes tablets, capsules, liquid orals, dry syrups, dry injections, β-lactam syrups, liquid injections, surgical products, lozenges, nasal drops, eye and ear preparations, creams, ointments, and medical devices. Afrinext has been recognized as a Star Export House by the Government of India, underscoring its significant contribution to the country's export sector.

What Does Afrinext Overseas Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Artesunate$3.9M

Product Portfolio — Top 3 by Export Value

Afrinext Overseas Private Limited exports 3 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Artesunate	Antimalarial & Antiparasitic	$3.9M	77	2.2%	4
2	Ibuprofen Paracetamol	Combination Drugs	$178.3K	48	9.3%	3
3	Paracetamol Caffeine	Combination Drugs	$17.3K	4	1.2%	9

Afrinext Overseas Private Limited exports 3 pharmaceutical products across 2 therapeutic categories with a total export value of $4.0M. The top category is Antimalarial & Antiparasitic (95.2% of portfolio), followed by Combination Drugs (4.8%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Afrinext Overseas Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Afrinext operates three WHO-GMP approved manufacturing facilities, each specializing in distinct product categories:

Plant 1: Focuses on general tablets, capsules, creams, and ointments.
Plant 2: Specializes in liquid orals.
Plant 3: Dedicated to β-lactam products, including tablets, capsules, and dry powder for suspension.

Strategically located near ports and airports, these facilities ensure efficient and timely delivery of products to global markets.

3Key Leadership

Afrinext is led by two directors:

Hitesh Lalwani: Serving as a director since April 13, 2017.
Nidhi Lalwani Hitesh: Also a director since April 13, 2017.

Both directors have been instrumental in steering the company towards its current growth trajectory.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Afrinext Overseas Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Afrinext's export data indicates a focus on markets in Africa, with shipments to countries such as Uganda, Cameroon, and Kenya. The company's adherence to WHO-GMP standards enhances its credibility in these regions, facilitating smoother market access.

2Emerging Markets

Afrinext's strategic focus on African markets, including Uganda, Cameroon, and Kenya, aligns with its goal to expand its global footprint. The company's compliance with WHO-GMP standards positions it favorably for market access in these regions.

3Geographic Strategy

Afrinext's export data reveals a concentration in African markets, particularly Uganda, Cameroon, and Kenya. This focus suggests a strategic emphasis on these regions, potentially exposing the company to market-specific risks. Diversifying its geographic presence could mitigate such risks and enhance overall stability.

TransData Nexus Research · FDA, EMA, WHO, MHRA, TGA databases

Afrinext Overseas Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Afrinext's FDA facility registrations, approved ANDAs, DMF filings, and inspection history are not publicly available. The company's adherence to WHO-GMP standards suggests a commitment to quality, which is essential for FDA approvals.

2WHO & EU GMP

Afrinext's manufacturing facilities are WHO-GMP approved, indicating compliance with international quality standards. However, there is no publicly available information regarding EU GMP certification or EDQM status.

3CDSCO & Indian Regulatory

Afrinext holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), ensuring compliance with Indian regulatory standards. The company's export data reflects adherence to national and international quality requirements, as evidenced by its Star Export House recognition.

Recent Regulatory Actions

Afrinext Overseas Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Afrinext operates in a competitive pharmaceutical export market, with key competitors likely including other Indian pharmaceutical exporters. While specific market share data is not available, Afrinext's focus on high-quality products and adherence to international standards position it favorably in the market.

2Key Differentiators

Afrinext's commitment to quality is demonstrated through its WHO-GMP approved manufacturing facilities and its Star Export House recognition. The company's diverse product portfolio and strategic focus on African markets further distinguish it in the pharmaceutical export sector.

3Strategic Position

Afrinext's current strategic direction emphasizes the export of finished pharmaceutical formulations, particularly targeting African markets. The company's adherence to international quality standards and its Star Export House recognition support this strategy. Future growth may involve diversifying its product offerings and expanding into additional international markets.

Buyer Due Diligence Brief — Evaluating Afrinext Overseas Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Afrinext's export data indicates a consistent volume of shipments, primarily to African markets. The company's adherence to WHO-GMP standards and its Star Export House recognition suggest reliability and a strong track record in the pharmaceutical export sector.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

WHO-GMP Certification: Confirm the validity of Afrinext's WHO-GMP certification by contacting the World Health Organization or reviewing the certificate directly.
EU GMP Certification: If applicable, verify EU GMP certification through the European Medicines Agency or the company's official documentation.
FDA Registration: Check the FDA's database for Afrinext's facility registrations and approved products.

Frequently Asked Questions — Afrinext Overseas Private Limited

How many pharmaceutical products does Afrinext Overseas Private Limited export from India?

Afrinext Overseas Private Limited exports 3 pharmaceutical products across 2 therapeutic categories. The top exports are Artesunate ($3.9M), Ibuprofen Paracetamol ($178.3K), Paracetamol Caffeine ($17.3K). Total export value is $4.0M.

What is Afrinext Overseas Private Limited's total pharmaceutical export value?

Afrinext Overseas Private Limited's total pharmaceutical export value is $4.0M, based on 129 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Afrinext Overseas Private Limited cover?

Afrinext Overseas Private Limited exports across 2 therapeutic categories. The largest are Antimalarial & Antiparasitic (95.2%, 1 products), Combination Drugs (4.8%, 2 products).

Get Full Afrinext Overseas Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.